Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Price, Quote, News and Overview

NASDAQ:IOVA - Nasdaq - US4622601007 - Common Stock - Currency: USD

1.74  -0.02 (-1.14%)

IOVA Quote, Performance and Key Statistics

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (5/22/2025, 10:39:39 AM)

1.74

-0.02 (-1.14%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High12.51
52 Week Low1.64
Market Cap581.04M
Shares333.93M
Float285.87M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO06-20 2008-06-20


IOVA short term performance overview.The bars show the price performance of IOVA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

IOVA long term performance overview.The bars show the price performance of IOVA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of IOVA is 1.74 USD. In the past month the price decreased by -44.98%. In the past year, price decreased by -82.47%.

IOVANCE BIOTHERAPEUTICS INC / IOVA Daily stock chart

IOVA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.62 320.03B
AMGN AMGEN INC 13.02 145.30B
GILD GILEAD SCIENCES INC 13.82 133.18B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.20B
REGN REGENERON PHARMACEUTICALS 13.5 64.59B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.23B
ARGX ARGENX SE - ADR 99.25 35.57B
ONC BEIGENE LTD-ADR 5.94 25.76B
BNTX BIONTECH SE-ADR N/A 23.59B
NTRA NATERA INC N/A 20.76B
SMMT SUMMIT THERAPEUTICS INC N/A 18.69B
BIIB BIOGEN INC 7.95 18.43B

About IOVA

Company Profile

IOVA logo image Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 838 full-time employees. The company went IPO on 2008-06-20. The firm develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The firm also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The firm is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Company Info

IOVANCE BIOTHERAPEUTICS INC

825 Industrial Road, 4th Floor

San Carlos CALIFORNIA 94070 US

CEO: Maria Fardis

Employees: 838

IOVA Company Website

IOVA Investor Relations

Phone: 16502607120

IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ

What is the stock price of IOVANCE BIOTHERAPEUTICS INC today?

The current stock price of IOVA is 1.74 USD. The price decreased by -1.14% in the last trading session.


What is the ticker symbol for IOVANCE BIOTHERAPEUTICS INC stock?

The exchange symbol of IOVANCE BIOTHERAPEUTICS INC is IOVA and it is listed on the Nasdaq exchange.


On which exchange is IOVA stock listed?

IOVA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IOVANCE BIOTHERAPEUTICS INC stock?

19 analysts have analysed IOVA and the average price target is 19.57 USD. This implies a price increase of 1024.45% is expected in the next year compared to the current price of 1.74. Check the IOVANCE BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IOVANCE BIOTHERAPEUTICS INC worth?

IOVANCE BIOTHERAPEUTICS INC (IOVA) has a market capitalization of 581.04M USD. This makes IOVA a Small Cap stock.


How many employees does IOVANCE BIOTHERAPEUTICS INC have?

IOVANCE BIOTHERAPEUTICS INC (IOVA) currently has 838 employees.


What are the support and resistance levels for IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

IOVANCE BIOTHERAPEUTICS INC (IOVA) has a resistance level at 1.92. Check the full technical report for a detailed analysis of IOVA support and resistance levels.


Is IOVANCE BIOTHERAPEUTICS INC (IOVA) expected to grow?

The Revenue of IOVANCE BIOTHERAPEUTICS INC (IOVA) is expected to grow by 81.52% in the next year. Check the estimates tab for more information on the IOVA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IOVANCE BIOTHERAPEUTICS INC (IOVA) stock pay dividends?

IOVA does not pay a dividend.


When does IOVANCE BIOTHERAPEUTICS INC (IOVA) report earnings?

IOVANCE BIOTHERAPEUTICS INC (IOVA) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of IOVANCE BIOTHERAPEUTICS INC (IOVA)?

IOVANCE BIOTHERAPEUTICS INC (IOVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.24).


What is the Short Interest ratio of IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

The outstanding short interest for IOVANCE BIOTHERAPEUTICS INC (IOVA) is 26.08% of its float. Check the ownership tab for more information on the IOVA short interest.


IOVA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

IOVA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IOVA. IOVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IOVA Financial Highlights

Over the last trailing twelve months IOVA reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS increased by 31.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -40.88%
ROE -52.39%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%14.29%
Sales Q2Q%6798.46%
EPS 1Y (TTM)31.11%
Revenue 1Y (TTM)13698.99%

IOVA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to IOVA. The Buy consensus is the average rating of analysts ratings from 19 analysts.

For the next year, analysts expect an EPS growth of 18.69% and a revenue growth 81.52% for IOVA


Ownership
Inst Owners82.91%
Ins Owners0.26%
Short Float %26.08%
Short Ratio5.9
Analysts
Analysts82.11
Price Target19.57 (1024.71%)
EPS Next Y18.69%
Revenue Next Year81.52%